← Leaderboards

John C Burnett

Mayo Clinic Coll Of Medicine, Rochester

Google Scholar ↗PubMed ↗ORCID ↗

$28,252,772

Attributed

$32,909,177

Total exposure

22

Grants

12

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY2005–22

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$72,459,935 · 25

By mechanism

P01$28,605,141 · 8

R01$19,371,554 · 7

M01$17,661,910 · 2

C06$4,620,000 · 5

P20$1,453,109 · 1

T32$498,221 · 1

Top collaborators

Most similar at Mayo Clinic Coll Of Medicine, Rochester

Same institution · by research overlap

Iftikhar J Kullo$21,946,679

Others in their field

Top investigators on “Peptides”

David M Nathan · Massachusetts Institute Of Technology$118,672,444
John M Lachin · George Washington University$118,672,444
David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
Michael W Weiner · Northern California Institute Res &Educ$78,425,041
Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
Rolf Apweiler · European Molecular Biology Laboratory$56,677,991

Research focus

PeptidesHeart FailureCardiovascular SystemNovel TherapeuticsCardiacCyclic GmpNatriuretic PeptidesChronicPropertyInnovationBaseKidneyAldosteroneBiologyReceptorAtrial Natriuretic Factor Receptor APharmaceutical PreparationsMyocardialParticulateHeartLeadCellsFibrosisMediating

Grant awards (101)

Novel Therapeutics for Cardiovascular Disease$715,647

R01 · FY2022 · HL

Novel Peptide Therapeutics for Hypertension$614,866

R01 · FY2021 · HL · contact PI

Novel Peptide Therapeutics for Hypertension$614,866

R01 · FY2020 · HL · contact PI

Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure$397,500

R01 · FY2020 · HL · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$651,411

R01 · FY2019 · AG

Novel Peptide Therapeutics for Hypertension$615,120

R01 · FY2019 · HL · contact PI

Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure$397,500

R01 · FY2019 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$397,500

R01 · FY2019 · HL · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$712,741

R01 · FY2018 · AG

Novel Peptide Therapeutics for Hypertension$617,993

R01 · FY2018 · HL · contact PI

Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure$397,500

R01 · FY2018 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$397,500

R01 · FY2018 · HL · contact PI

Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers$645,210

R01 · FY2017 · AG

Small Molecule Discovery for GC-A Activators$458,660

R01 · FY2017 · DK · contact PI

Cardiac Peptides in Cardiorenal Protection$397,500

R01 · FY2017 · HL · contact PI

Novel Peptide Therapeutics for Cardiorenal Protection in Heart Failure$397,500

R01 · FY2017 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$539,884

R01 · FY2016 · HL · contact PI

Small Molecule Discovery for GC-A Activators$533,169

R01 · FY2016 · DK · contact PI

Cardiac Peptides in Cardiorenal Protection$397,500

R01 · FY2016 · HL · contact PI

Biology and Novel Therapeutics of Cardiovascular Peptides$1,882,473

P01 · FY2015 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$531,785

R01 · FY2015 · HL · contact PI

Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction$489,673

P01 · FY2015 · HL · contact PI

Small Molecule Discovery for GC-A Activators$422,064

R01 · FY2015 · DK · contact PI

Novel Natriuretic Peptides and Delivery for Cardiorenal Disease$315,765

P01 · FY2015 · HL · contact PI

Biochemical and Neurohumoral Core$278,203

P01 · FY2015 · HL · contact PI

Administrative Core$168,105

P01 · FY2015 · HL · contact PI

Biology and Novel Therapeutics of Cardiovascular Peptides$1,872,916

P01 · FY2014 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$529,087

R01 · FY2014 · HL · contact PI

Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction$488,081

P01 · FY2014 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$382,501

R01 · FY2014 · HL · contact PI

Novel Natriuretic Peptides and Delivery for Cardiorenal Disease$314,172

P01 · FY2014 · HL · contact PI

Biochemical and Neurohumoral Core$276,610

P01 · FY2014 · HL · contact PI

Administrative Core$166,512

P01 · FY2014 · HL · contact PI

Biology and Novel Therapeutics of Cardiovascular Peptides$1,822,223

P01 · FY2013 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$513,971

R01 · FY2013 · HL · contact PI

Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction$479,138

P01 · FY2013 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$371,573

R01 · FY2013 · HL · contact PI

Novel Natriuretic Peptides and Delivery for Cardiorenal Disease$305,229

P01 · FY2013 · HL · contact PI

Biochemical and Neurohumoral Core$267,668

P01 · FY2013 · HL · contact PI

Administrative Core$157,569

P01 · FY2013 · HL · contact PI

Biology and Novel Therapeutics of Cardiovascular Peptides$1,916,871

P01 · FY2012 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$539,884

R01 · FY2012 · HL · contact PI

Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction$494,451

P01 · FY2012 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$390,308

R01 · FY2012 · HL · contact PI

Novel Natriuretic Peptides and Delivery for Cardiorenal Disease$320,543

P01 · FY2012 · HL · contact PI

Biochemical and Neurohumoral Core$282,980

P01 · FY2012 · HL · contact PI

Administrative Core$172,882

P01 · FY2012 · HL · contact PI

Biology and Novel Therapeutics of Cardiovascular Peptides$1,988,914

P01 · FY2011 · HL · contact PI

Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction$702,819

P20 · FY2011 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$394,250

R01 · FY2011 · HL · contact PI

Novel Natriuretic Peptides and Delivery for Cardiorenal Disease$392,585

P01 · FY2011 · HL · contact PI

Biochemical and Neurohumoral Core$282,980

P01 · FY2011 · HL · contact PI

Administrative Core$172,882

P01 · FY2011 · HL · contact PI

Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction$750,290

P20 · FY2010 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$394,250

R01 · FY2010 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$2,074,421

P01 · FY2009 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$508,284

R01 · FY2009 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$359,270

R01 · FY2009 · HL · contact PI

Core--Neurohumoral$345,737

P01 · FY2009 · HL · contact PI

Natriuretic Peptide System and Cardiac Fibrosis$345,737

P01 · FY2009 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$1,996,047

P01 · FY2008 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$489,841

R01 · FY2008 · HL · contact PI

Natriuretic Peptide System and Cardiac Fibrosis$402,857

P01 · FY2008 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$359,270

R01 · FY2008 · HL · contact PI

Core--Neurohumoral$223,510

P01 · FY2008 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$1,979,640

P01 · FY2007 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$491,656

R01 · FY2007 · HL · contact PI

Natriuretic Peptide System and Cardiac Fibrosis$384,952

P01 · FY2007 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$359,270

R01 · FY2007 · HL · contact PI

Core--Neurohumoral$222,647

P01 · FY2007 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$69,674

P01 · FY2007 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$1,994,515

P01 · FY2006 · HL · contact PI

Cardiovascular Peptides and Myocardial Infarction$494,180

R01 · FY2006 · HL · contact PI

Natriuretic Peptide System and Cardiac Fibrosis$384,757

P01 · FY2006 · HL · contact PI

Cardiac Peptides in Cardiorenal Protection$370,000

R01 · FY2006 · HL · contact PI

Core--Neurohumoral$221,693

P01 · FY2006 · HL · contact PI

Biology and Therapeutics of Cardiovascular Peptides$1,981,154

P01 · FY2005 · HL

Natriuretic Peptide System and Cardiac Fibrosis$376,216

P01 · FY2005 · HL

Core--Neurohumoral$216,145

P01 · FY2005 · HL

Administrative Core$76,014

P01 · FY2005 · HL

GENERAL CLINICAL RESEARCH CENTER$4,970,862

M01 · FY2004 · RR

EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM$2,310,000

C06 · FY2004 · RR

EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,$577,500

C06 · FY2004 · RR

EXTRAMURAL RES FACIL IMPROVEMENT PROG:CARDIOVASCULAR &CEREBRAL STUDIES, INTRACR$577,500

C06 · FY2004 · RR

EXTRAMURAL RES FACIL IMPROVEMENT PROG: CANCER, BREAST CANCER$577,500

C06 · FY2004 · RR

EXTRAMURAL RES FACIL IMPROVEMENT PROG: ALZHEIMER'S DISEASE$577,500

C06 · FY2004 · RR

Intrarenal Regulation of Sodium Excretion$321,750

R01 · FY2004 · HL

GENERAL CLINICAL RESEARCH CENTER$4,830,830

M01 · FY2003 · RR

Intrarenal Regulation of Sodium Excretion$321,750

R01 · FY2003 · HL

Informatics Support to Enhance Human Subjects Research$250,000

S07 · FY2003 · RR

GCRC Mass Spectrometry Core Facility Supplement$232,521

M01 · FY2003 · RR

GENERAL CLINICAL RESEARCH CENTER$4,165,415

M01 · FY2002 · RR

CARDIOVASOLOGY$344,676

T32 · FY2002 · HL

Intrarenal Regulation of Sodium Excretion$321,750

R01 · FY2002 · HL

CARDIORENAL &ENDOCRINE RESPONSE TO SC BNP IN MILD CHF$0

M01 · FY2002 · RR

GENERAL CLINICAL RESEARCH CENTER$3,462,282

M01 · FY2001 · RR

Intrarenal Regulation of Sodium Excretion$321,750

R01 · FY2001 · HL

CARDIORENAL &ENDOCRINE RESPONSE TO SC BNP IN MILD CHF$0

M01 · FY2001 · RR

INTRARENAL REGULATION OF SODIUM EXCRETION$283,543

R01 · FY2000 · HL

CARDIOVASOLOGY$153,545

T32 · FY2000 · HL

CARDIORENAL &ENDOCRINE RESPONSE TO SC BNP IN MILD CHF$0

M01 · FY2000 · RR